Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131537 | 0.87 | CYP11B1 (0.43) | IRAK4CYP1A2CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL4147560 | 0.82 | CYP11B1 (0.40) | IRAK4CYP1A2CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL4144743 | 0.79 | PIK3CA (0.42) | IRAK4CYP1A2CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL4127534 | 0.79 | CYP11B2 (0.46) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL4136683 | 0.77 | JAK3 (0.51) | CYP3A4 | |
| SCHEMBL24740620 | 0.77 | GAA (0.43) | IRAK4 | |
| SCHEMBL2085878 | 0.76 | FAAH (0.54) | IRAK4CYP11B2 | |
| SCHEMBL13102446 | 0.76 | LMNA (0.44) | IRAK4 | |
| SCHEMBL4135895 | 0.76 | CYP11B1 (0.40) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL4141084 | 0.75 | JAK2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | IRAK4 1839/4885CYP1A2 1220/4885CYP11B1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.